Acute antipyschotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1562-1566

  Dolžan, Vita ^a   Serretti, Alessandro ^b   Mandelli, Laura ^b   Koprivšek, Jure ^c   Kastelic, Matej ^a   Plesničar, Blanka Kores ^c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

5 HTTLPR; Antipsychotics; Schizophrenia; Treatment efficacy

Indexed keywords

ANXIOLYTIC AGENT; DIAZEPAM; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN; SEROTONIN TRANSPORTER;

5 HTT GENE; ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGE; AKATHISIA; ALLELE; ARTICLE; BARNES AKATHISIA SCALE; BODY MASS; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; EXTRAPYRAMIDAL SIDE EFFECTS SCALE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIVIDUALIZATION; L ALLELE VARIANT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROMOTER REGION; PSYCHOSIS; RATING SCALE; RELAPSE; RISK FACTOR; S ALLELE VARIANT; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SEROTONIN RELEASE; SEROTONINERGIC TRANSMISSION; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC MARKERS; GENOTYPE; HALOPERIDOL; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 47749153710     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.05.022     Document Type: Article

References (52)

1. Abou-Sleiman P.M., Hanna M.G., and Wood N.W. Genetic association studies of complex neurological diseases. J Neurol Neurosurg Psychiatry 77 (2006) 1302-1304
2. Benaliouad F., Kapur S., and Rompre P.P. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 32 (2007) 551-561
3. Bozina N., Medved V., Kuzman M.R., Sain I., and Sertic J. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 21 (2007) 728-734
4. Chong S.A., Tan E.C., Tan C.H., Mahendren R., Tay A.H., and Chua H.C. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. Am J Med Genet 96 (2000) 712-715
5. Cohen J. Statistical power analysis for the behavioral sciences (1988), Lawrence Erlbaum Associates, Hillsdale, New Jersey
6. Davis J.M., and Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24 (2004) 192-208
7. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15 (1995) 821-829
8. Dubertret C., Hanoun N., Ades J., Hamon M., and Gorwood P. Family-based association study of the 5-HT transporter gene and schizophrenia. Int J Neuropsychopharmacol 8 (2005) 87-92
9. Gelernter J., Kranzler H., and Cubells J.F. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 101 (1997) 243-246
10. Gelernter J., Cubells J.F., Kidd J.R., Pakstis A.J., and Kidd K.K. Population studies of polymorphisms of the serotonin transporter protein gene. American Journal of Medical Genetics 88 (1999) 61-66
11. Gingrich J.A., and Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berl) 155 (2001) 1-10
12. Greenberg B.D., Tolliver T.J., Huang S.J., Li Q., Bengel D., and Murphy D.L. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 88 (1999) 83-87
13. Guzey C., Scordo M.G., Spina E., Landsem V.M., and Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 63 (2007) 233-241
14. Heils A., Teufel A., Petri S., Stöber G., Riederer P., Bengel D., et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 66 (1996) 2621-2624
15. Herken H., Erdal M.E., Boke O., and Savas H.A. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 18 (2003) 77-81
16. Hranilovic D., Stefulj J., Schwab S., Borrmann-Hassenbach M., Albus M., Jernej B., et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry 55 (2004) 1090-1094
17. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78 (2006) 815-826
18. Ishikane T., Kusumi I., Matsubara R., Matsubara S., and Koyama T. Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Eur J Pharmacol 321 (1997) 163-169
19. Javors M.A., Seneviratne C., Roache J.D., Ait-Daoud N., Bergeson S.E., Walss-Bass M.C., et al. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 7-13
20. Kaiser R., Tremblay P.B., Schmider J., Henneken M., Dettling M., Muller-Oerlinghausen B., et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 6 (2001) 179-185
21. Kapur S., and Remigton G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153 (1996) 466-476
22. Kendler K.S. "A gene for...": the nature of gene action in psychiatric disorders. Am J Psychiatry 162 (2005) 1243-1252
23. Kraft J.B., Slager S.L., McGrath P.J., and Hamilton S.P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58 (2005) 374-381
24. Lerman C., Shields P.G., Audrain J., Main D., Cobb B., Boyd N.R., et al. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev 7 (1998) 253-255
25. Lesch K.P. Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur Neuropsychopharmacol 11 (2001) 457-474
26. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
27. Malhotra A.K., Goldman D., Mazzanti C., Clifton A., Breier A., and Pickar D. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiatry 3 (1998) 328-332
28. Nocjar C., Roth B.L., and Pehek E.A. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 111 (2002) 163-176
29. Owens M.J., and Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40 (1994) 288-295
30. Pae C.U., Kim J.J., Lee S.J., Lee C.U., Lee C., Paik I.H., et al. Polymorphism of the serotonin transporter gene and symptomatic dimensions of schizophrenia in the Korean population. Neuropsychobiology 47 (2003) 182-186
31. Pae C.U., Serretti A., Artioli P., Kim T.S., Kim J.J., Lee C.U., et al. Interaction analysis between 5-HTTLPR and TNFA-238/-308 polymorphisms in schizophrenia. J Neural Transm 113 (2006) 887-897
32. Pehek E.A., Nocjar C., Roth B.L., Byrd T.A., and Mabrouk O.S. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress-and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31 (2006) 265-277
33. Pritchard J.K., and Rosenberg N.A. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65 (1999) 220-228
34. Sawa A., and Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science 296 (2002) 692-695
35. Schmidt C.J., and Fadayel G.M. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 277 (1996) 1541-1549
36. Segman R.H., Heresco-Levy U., Finkel B., Goltser T., Shalem R., Schlafman M., et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6 (2001) 225-229
37. Segman R.H., Goltser T., Heresco-Levy U., Finkel B., Shalem R., Schlafman M., et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 3 (2003) 277-283
38. Serretti A., Catalano M., and Smeraldi E. Serotonin transporter gene is not associated with symptomatology of schizophrenia. Schizophr Res 35 (1999) 33-39
39. Serretti A., De Ronchi D., Lorenzi C., and Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 11 (2004) 343-358
40. Serretti A., Calati R., Mandelli L., and De Ronchi D. Serotonin transporter gene variants and behaviour: a comprehensive review. Current Drug Targets 7 (2006) 1659-1669
41. Serretti A., Kato M., De Ronchi D., and Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12 (2007) 247-257
42. Siebert G.A., Pond S.M., and Bryan-Lluka L.J. Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells. Naunyn Schmiedebergs Arch Pharmacol 361 (2000) 255-264
43. Stahl S.M., and Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11 (2004) 313-327
44. Stein M.B., Seedat S., and Gelernter J. Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 187 (2006) 68-72
45. Teshima K.M., and Przeworski M. Directional positive selection on an allele of arbitrary dominance. Genetics 172 (2006) 713-718
46. Tiilikainen A., Fischer G., Grubic Z., Gyodi E., Ivaskova E., Jungerman M., et al. Anthropological features of the East European region. In: Charron D., and Paris E.D.K. (Eds). HLA: genetic diversity of HLA functional and medical implication. Proceedings of the 12th International Histocompatibility Workshop and Conference 1 (1997), Medical and scientific international publisher 307-313
47. Tsai S.J., Hong C.J., Yu Y.W., Lin C.H., Song H.L., Lai H.C., et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res 44 (2000) 177-181
48. Vidan-Jeras B., Jurca B., Dolzan V., Jeras M., Breskvar K., and Bohinjec M. Caucasian Slovenian normal. HLA 1998. In: Gjertson D.W., and Terasaki P.I. (Eds). Lenexa, American Society for Histocompatibility and Immunogenetics (1998) 180-181
49. Wang L., Yu L., He G., Zhang J., Zhang A.P., Du J., et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 414 (2007) 1-4
50. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 (2003) 663-667
51. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., and Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788 (1998) 215-222
52. Zaboli G., Jonsson E.G., Gizatullin R., De Franciscis A., Asberg M., and Leopardi R. Haplotype analysis confirms association of the serotonin transporter (5-HTT) gene with schizophrenia but not with major depression. Am J Med Genet B Neuropsychiatr Genet 147 (2008) 301-307